Valuation: Arvinas, Inc.

Market Cap 540M 471M 446M 404M 755M 51.82B 762M 5.32B 2.05B 26.28B 2.03B 1.98B 84.36B P/E 2026 *
-367x
P/E 2027 * -2.37x
Enterprise Value 89.35M 77.95M 73.73M 66.76M 125M 8.57B 126M 880M 340M 4.35B 336M 328M 13.96B EV / Sales 2026 *
0.3x
EV / Sales 2027 * 3.63x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.21%
1 week-10.13%
Current month-11.30%
1 month-9.03%
3 months+8.95%
6 months-33.00%
Current year-31.20%
1 week 8.05
Extreme 8.05
8.92
1 month 8.05
Extreme 8.05
9.74
Current year 6.97
Extreme 6.97
14.51
1 year 6.97
Extreme 6.97
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 11/02/2026
Director of Finance/CFO 56 23/06/2024
Chief Tech/Sci/R&D Officer 58 16/06/2024
Director TitleAgeSince
Chairman 66 14/06/2023
Director/Board Member 64 30/06/2018
Chairman 67 11/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%-10.13%+5.43%-66.56% 540M
+0.66%+0.87%+47.39%+97.63% 69.18B
-1.19%-1.99%+33.01%+73.08% 62B
+2.22%-1.85%-14.36%+360.65% 26.19B
+1.46%+1.30%+28.58%+13.76% 25.75B
-0.89%-2.87%-2.09%-15.24% 24.29B
+2.84%+2.12%+24.28%-17.13% 19.84B
0.00%-14.23%+170.04%+298.75% 15.65B
-0.57%+0.12%-8.66%+825.13% 13.88B
-0.39%-5.61%-9.51%+483.04% 14.09B
Average +0.29%-2.62%+27.41%+205.31% 27.14B
Weighted average by Cap. +0.33%-1.00%+31.42%+159.44%

Financials

2026 *2027 *
Net sales 296M 258M 244M 221M 414M 28.41B 418M 2.92B 1.13B 14.41B 1.11B 1.09B 46.25B 64.19M 56M 52.97M 47.97M 89.79M 6.16B 90.59M 632M 244M 3.12B 241M 236M 10.03B
Net income -666K -581K -550K -498K -932K -63.94M -940K -6.56M -2.53M -32.42M -2.5M -2.45M -104M -248M -216M -205M -185M -347M -23.78B -350M -2.44B -942M -12.06B -931M -910M -38.71B
Net Debt -451M -393M -372M -337M -630M -43.25B -636M -4.44B -1.71B -21.93B -1.69B -1.66B -70.4B -307M -268M -253M -229M -429M -29.44B -433M -3.02B -1.17B -14.93B -1.15B -1.13B -47.92B
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
16/09/26 US$8.160 -1.21% 742,605
15/09/26 US$8.260 -1.67% 2,523,154
14/09/26 US$8.400 -0.59% 1,471,571
11/09/26 US$8.450 -2.99% 908,559
10/09/26 US$8.710 -0.57% 776,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
8.260USD
Average target price
13.93USD
Spread / Average Target
+68.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARVN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!